Abstract

The current population is characterized by a high prevalence of risk factors for the development of chronic kidney disease: hypertension, diabetes, obesity, metabolic syndrome, physical inactivity, smoking. The development of severe complications and a close connection with potentially fatal cardiovascular disorders make this disease a socially and economically significant problem. Treatment of chronic kidney disease in advanced stages belong to nephrologist duties. However, the success of preventive interventions depends on the time of their onset, which makes it relevant to identify the disease. The use of nephroprotective approaches by physicians of different specialties (general practitioners, cardiologists, gerontologists, nephrologists, endocrinologists) can significantly improve the prognosis of both those at risk of developing renal dysfunction and the existing disease. The review presents data on the clinical and laboratory efficacy of angiotensin-renin blocker use, as well as the combination of angiotensin II receptor blockers with calcium antagonists. Using the combination of the angiotensin II receptor blocker irbesartan and amlodipine as an example, we demonstrated the possibilities of nephroprotective therapy in patients with renal dysfunction.

Highlights

  • Современное население характеризуется высокой распространенностью факторов риска развития хронической болезни почек: артериальной гипертензии, сахарного диабета, ожирения, метаболического синдрома, гиподинамии, курения

  • The current population is characterized by a high prevalence of risk factors for the development of chronic kidney disease: hypertension, diabetes, obesity, metabolic syndrome, physical inactivity, smoking

  • Treatment of chronic kidney disease in advanced stages belong to nephrologist duties

Read more

Summary

Ингибиторы АПФ

ESPIRAL (Efecto del tratamiento antihipertensivo Sobrela Progresión dela Insuficiencia RenAL en pacientes no diabéticos) [38]. Angiotensin-ConvertingEnzyme Inhibition in Progressive Renal Insufficiency Study (AIPRI) [41]

Беназеприл или плацебо
Кандесартан и амлодипин
Findings
Телмисартан или рамиприл или их комбинация
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call